WiSA Technologies, Inc. (Nasdaq: WISA) said that it is now accepting pre-orders for its WiSA E development kits, featuring advanced wireless audio transmission and reception capabilities utilizing the 5GHz Wi-Fi band. This cutting-edge technology provides high-performance and high-quality wireless audio at an affordable price point. 

Due to the strong market demand, WiSA encourages customers to pre-order the development kits to ensure ample inventory and prompt delivery.

$WISA is currently tradin at $1.82 in pre-market, reflecting an increase of $0.53 (+41.08%), following the announcement.

In other news, 2seventy bio, Inc. (Nasdaq: TSVT) has temporarily paused the Phase 1 trial of the PLAT-08 study involving SC-DARIC33 for Acute Myeloid Leukemia (AML). 

This decision was made in accordance with the clinical study protocol's stopping rules following a recent Grade 5 serious adverse event (SAE), which tragically resulted in the loss of a patient's life. 

Seattle Children's, the company's partner and regulatory sponsor of the study, promptly notified the U.S. Food & Drug Administration (FDA) as per the requirements. Currently, investigations are underway to determine the root cause of this SAE and its potential connection to the study drug.

$TSVT is currently trading at $10.90, down $0.91 (-7.71%) in pre-market

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)